Patent details

Basic Information

Publication number:

EP2418217

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP110039856

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

Cell-permeable peptide inhibitors of the JNK signal transduction pathway

French Title of Invention:

Inhibiteurs peptidiques perméables aux cellules de la voie de transduction de signal JNK

German Title of Invention:

Zelldurchlässige Peptidhemmer des JNK-Signaltransduktionsweges

SPC Number:

Dates

Filing date:

12/09/2006

Grant date:

27/01/2016

EP Publication Date:

27/01/2016

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

15/02/2012

EP B1 Publication Date:

27/01/2016

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

12/09/2019

Expiration date:

12/09/2026

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

12/09/2006

 

 

Name:

Xigen Inflammation Ltd.

Address:

Arch. Makariou III 195 Neocleous House, 3030 Limassol, Cyprus (CY)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

24/02/2016

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

Name:

Bonny Christophe

Address:

Switzerland (CH)

Priority

Priority Number:

5/009782

Priority Date:

12/09/2005

Priority Country:

European Patent Office (EPO) (EP)

Classification

Main IPC Class:

C07K 14/47;

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

19/02/2019

Last Annual Fee Paid Number:

13

Last Annual Fee Paid Amount:

180 Euro

Payer:

PAVIS GMBH

Filing date	Document type	Number of pages
30/01/2019	Outgoing Correspondence	1